Insulin-like growth factor-1 induces epithelial-mesenchymal transition in hepatocellular carcinoma by activating survivin

被引:35
|
作者
Liu, Fangfeng [1 ]
Sun, Yongjie [1 ]
Liu, Bingqi [1 ]
Lu, Jun [1 ]
Li, Hongguang [1 ]
Zhu, Huaqiang [1 ]
Gao, Hengjun [1 ]
Zhou, Xu [1 ]
Chang, Hong [1 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Hepatobiliary Surg, 9677 Jingshi Rd, Jinan 250021, Shandong, Peoples R China
关键词
insulin-like growth factor 1; epithelial-mesenchymal transition; survivin; hepatocellular carcinoma; CANCER-CELLS; METASTASIS; EXPRESSION; INHIBITION; PROMOTES; SYSTEM; SNAIL; EMT;
D O I
10.3892/or.2018.6516
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Insulin-like growth factor-1 (IGF-1), a small polypeptide hormone similar to insulin in protein structures, has been identified as an activator of epithelial-mesenchymal transition (EMT) pathways in several types of cancers. As a member of the inhibitor of apoptosis protein (IAP) family, survivin is implicated in the EMT of some cancers. However, the role of survivin on IGF-1-mediated EMT of hepatocellular carcinoma (HCC) has not been clarified. In the present study, we demonstrated that survivin was involved in the EMT process induced by IGF-1 in HCC cell line SMMC7721. With administration of different concentrations of IGF-1, survivin mRNA and protein expression were significantly increased and stimulated EMT in the tested cell line, while the increased invasive and migratory abilities of HCC cells and activation of the EMT process induced by IGF-1 were reversed after silencing of survivin expression by transfecting small interfering RNA. This was further confirmed by the observation of morphological changes, the decrease of invasive and migratory abilities and the downregulation of EMT markers, N-cadherin, vimentin and Snail, and the upregulation of E-cadherin. In conclusion, survivin may play a vital role in the IGF-1 signaling pathway by mediating EMT in HCC through the upregulation of the expression of EMT markers, and the knockdown of survivin expression may suppress the metastasis of HCC, which may provide new insights for the molecular therapy of HCC patients in clinical treatment.
引用
收藏
页码:952 / 958
页数:7
相关论文
共 50 条
  • [21] Growth Hormone and Insulin-Like Growth Factor-1
    Nicholls, Adam R.
    Holt, Richard I. G.
    SPORTS ENDOCRINOLOGY, 2016, 47 : 101 - 114
  • [22] Suppression of epithelial-mesenchymal transition in hepatocellular carcinoma cells by Kruppel-like factor 4
    Li, Qi
    Song, Weifeng
    Wang, Weiyu
    Yao, Shanshan
    Tian, Chuan
    Cai, Xun
    Wang, Liwei
    ONCOTARGET, 2016, 7 (20) : 29749 - 29760
  • [23] Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort
    Yvonne Huber
    Franziska Bierling
    Christian Labenz
    Sandra Koch
    Irene Schmidtmann
    Roman Kloeckner
    Sebastian Schotten
    Tobias Huber
    Hauke Lang
    Marcus A. Woerns
    Peter R. Galle
    Arndt Weinmann
    Julia Weinmann-Menke
    BMC Cancer, 18
  • [24] Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort
    Huber, Yvonne
    Bierling, Franziska
    Labenz, Christian
    Koch, Sandra
    Schmidtmann, Irene
    Kloeckner, Roman
    Schotten, Sebastian
    Huber, Tobias
    Lang, Hauke
    Woerns, Marcus A.
    Galle, Peter R.
    Weinmann, Arndt
    Weinmann-Menke, Julia
    BMC CANCER, 2018, 18
  • [25] Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
    Kaseb, Ahmed O.
    Xiao, Lianchun
    Hassan, Manal M.
    Chae, Young Kwang
    Lee, Ju-Seog
    Vauthey, Jean-Nicolas
    Krishnan, Sunil
    Cheung, Sheree
    Hassabo, Hesham M.
    Aloia, Thomas
    Conrad, Claudius
    Curley, Steven A.
    Vierling, John M.
    Jalal, Prasun
    Raghav, Kanwal
    Wallace, Michael
    Rashid, Asif
    Abbruzzese, James L.
    Wolff, Robert A.
    Morris, Jeffrey S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (05):
  • [26] Insulin-like growth factor II in hepatocellular carcinoma
    Jeng, Jeng-Eing
    Chuang, Lea-Yea
    Chuang, Wang-Lung
    Chang, Jan-Gowth
    Tsai, Jung-Fa
    BIOMARKERS IN MEDICINE, 2007, 1 (02) : 261 - 271
  • [27] Doxorubicin Impairs the Insulin-Like Growth Factor-1 System and Causes Insulin-Like Growth Factor-1 Resistance in Cardiomyocytes
    Fabbi, Patrizia
    Spallarossa, Paolo
    Garibaldi, Silvano
    Barisione, Chiara
    Mura, Marzia
    Altieri, Paola
    Rebesco, Barbara
    Monti, Maria Gaia
    Canepa, Marco
    Ghigliotti, Giorgio
    Brunelli, Claudio
    Ameri, Pietro
    PLOS ONE, 2015, 10 (05):
  • [28] Overexpression of Insulin-like Growth Factor-1 Is Associated with Chemoresistance and Poor Outcome of Epithelial Ovarian Carcinoma
    Cheng, W. F.
    Huang, C. T.
    Chou, C. Y.
    Chen, Y. L.
    Chen, C. A.
    Hsu, H. C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 659 - 659
  • [29] Insulin-like growth factor-1 modulation of intestinal epithelial cell restitution
    Chen, K
    Nezu, R
    Wasa, M
    Sando, K
    Kamata, S
    Takagi, Y
    Okada, A
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 1999, 23 (05) : S89 - S92
  • [30] Hypoxia-inducible factor-1α induces the epithelial-mesenchymal transition of human prostatecancer cells
    LUO Yong HE Dalin NING Liang SHEN Shulin LI Lei and LI Xiang Department of Urology First Hospital of Xian Jiaotong University Xian China
    Chinese Medical Journal, 2006, (09) : 713 - 718